Navigation Links
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
Date:4/29/2009

lfa-2a) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in treatment-naive patients with genotype 1 chronic hepatitis C. As previously reported, Albuferon also met its primary endpoint in ACHIEVE 2/3, which was conducted in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C.

The results of both trials were presented on April 25 in the late-breaker session at the 44th annual meeting of the European Association for the Study of the Liver (EASL) in Copenhagen. The Phase 3 data demonstrate that, with half as many injections, in two pivotal Phase 3 trials, Albuferon achieved efficacy comparable to Pegasys with a positive safety profile. The submission of global marketing applications for Albuferon is planned in fall 2009, following discussions with the FDA and other regulatory authorities. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

LymphoStat-B(R) Phase 3 Results Expected in July and November 2009

HGS expects to report the first Phase 3 data for LymphoStat-B (belimumab) in July 2009 from the BLISS-52 trial, with results from BLISS-76 anticipated in November 2009. BLISS-52 and BLISS-76 are the largest clinical trials ever conducted in lupus patients. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

$9 Million Milestone Payment Received from GSK Following Initiation of Phase 3 Development of Syncria(R)

HGS received a $9.0 million milestone payment during the first quarter of 2009, following GSK's initiation of a Phase 3 clinical trial program to evaluate Syncria (albiglutide) in the long-term treatment of type 2 diabetes mellitus. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled t
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 The SNIS Foundation recognized its ... fund a translational research project.  The first award ... was presented at the Society of NeuroInterventional Surgery ... Colorado Springs, CO. ... neurovascular conditions, SNIS formed the SNIS Foundation, in ...
(Date:7/31/2014)... 31, 2014 Graphite Metallizing Corporation announces ... oven carts. These bearings are uniquely suited to prevent ... bearings because of the high temperatures . , ... from the design engineers at Graphite Metallizing to overcome ... During their manufacturing operation, pans containing blocks of powder ...
(Date:7/31/2014)... DUBLIN , July 31, 2014 ... the "Global Genomics Market 2014-2018" report to ... Genomics is the study of the genetic ... to be a strong basis for the discovery and ... of human diseases or health conditions. Genomics is supported ...
(Date:7/31/2014)... , July 31, 2014  Smith & ... global medical technology business, today announced its entry ... the HAT-TRICK™ Lesser Toe Repair System. Comprised of ... products for metatarsophalangeal (MTP) ligament repair and reconstruction, ... implant for proximal Inter-phalanges (PIP) fusion, also known ...
Breaking Biology Technology:SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4
... April 1, 2008 Cardium Therapeutics,(Amex: ... Therapies announced today that,InnerCool has entered into ... (Euromed), a leading distributor of cardiology,medical products. ... will have,exclusive marketing, sales and distribution rights ...
... April 1, 2008 Piedmont Heart Institute (PHI),expands ... cardiovascular,physician practice, Cardiology of Georgia, P.C. (COG), through ... 2008. With eight,locations including Buckhead, Canton, Fayetteville and ... under the Piedmont Heart Institute and an,important addition ...
... 1, 2008 ,Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... Loar has been appointed Chief,Financial Officer. Mr. Loar will ... joins the company from Osteologix, where he has served,as ... proven track record as a chief financial officer, and ...
Cached Biology Technology:Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Piedmont Heart Institute Welcomes Cardiology of Georgia 2Piedmont Heart Institute Welcomes Cardiology of Georgia 3Piedmont Heart Institute Welcomes Cardiology of Georgia 4Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 2Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 3
(Date:7/30/2014)... University is paving the way for a breakthrough ... military troops exposed to poisonous chemicalsparticularly those in ... in the current issue of the journal ... which are compounds commonly used in pesticides and ... NYU School of Engineering Associate Professor of Chemical ...
(Date:7/30/2014)... Carroll,s Through the Looking Glass, collaborators from the ... improved a 35-year-old ecology model to better understand ... years. , The new model, called a mean ... Effect," an evolutionary hypothesis introduced by Lee Van ... must constantly increase their fitness (or ability to ...
(Date:7/30/2014)... American Chemical Society (ACS) announced today that David L. ... ACS Biomaterials Science & Engineering as editor-in-chief. With ... the new journal will feature high-quality research in the ... or naturally derived materials that interact with living or ... it reflects the tremendous growth in the field of ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... interdisciplinary perspective. Presenters at the National Academy of Sciences, ... ways to identify, encourage, and support advances in climate ... other fields. In addition, U.S. Secretary ... Sackler Lecture beginning at 6 p.m. on March 31 ...
... Providing further understanding of the link between low birth ... deprived newborns are "programmed" to eat more because they ... that controls food intake, according to an article published ... The study by a team of researchers at Los ...
... of people commit suicide worldwide each year, researchers and ... person,s likelihood of thinking about or trying to commit ... Hospital del Mar Research Institute (IMIM) has participated, has ... suicides. "It is of key importance to identify suicidal ...
Cached Biology News:Study provides explanation for connection between low birth weight and obesity later in life 2First international index developed to predict suicidal behavior 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
Biology Products: